Advertisement


William G. Wierda, MD, PhD, on Updates to the Management of CLL

2015 NCCN Annual Conference

Advertisement

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.



Related Videos

Colorectal Cancer

Axel Grothey, MD, on Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer

Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.

Breast Cancer

Robert W. Carlson, MD, and William J. Gradishar, MD, on Optimizing Treatment of HER2-Positive Breast Cancer

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of the breast cancer guidelines, the inclusion of varied fields––such as plastic surgery, pathology, patient advocacy, and radiation–– and new treatment changes.

Lung Cancer

Gregory A. Otterson, MD, on Adjuvant Therapy and Immunotherapy for Lung Cancer

Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.

Bladder Cancer

Peter E. Clark, MD, on a Guideline Update in the Management of Bladder Cancer

Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.

Skin Cancer

John A. Thompson, MD, on Treatment Options for Advanced Melanoma

John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the latest immunotherapeutics for advanced melanoma, including pembrolizumab, trametinib, nivolumab, and dabrafenib.

Advertisement

Advertisement




Advertisement